Chen Guoming, Xie Yaying, Liu Yunyun, Jin Shanmi, Chen Ziyin, Zhang Peng, Shi Peiyu, Zhu Junxia, Deng Jieyi, Liang Haorui, Zhou Chi
Guangzhou University of Chinese Medicine.
Department of Orthopedics, First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Medicine (Baltimore). 2020 Mar;99(13):e19368. doi: 10.1097/MD.0000000000019368.
Femoral head necrosis is one of the most common orthopedic diseases which can be diagnosed in all ages with different reasons. Taohong Siwu decoction (TSD) has been widely used in the treatment of femoral head necrosis. However, as far as we know, there is still a lack of supporting evidence regarding the efficacy of TSD for femoral head necrosis. Therefore, this protocol aims to evaluate the effectiveness and safety of TSD for femoral head necrosis.
Eight electronic databases, including PubMed, the Cochrane Central Register of Controlled Trials, EMBASE, Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Technology Periodical database, (Chinese Scientific Journal Database) and Wanfang Database will be searched from the time when the respective databases were established to January 2020. Randomized controlled trials of TSD in the treatment of femoral head necrosis will be collected. After evaluating the quality of methodology and extracting valid data, the final meta-analysis will be carried out with software Revman 5.3.
The results of this systematic review will offer implications of the use of TSD treatment for Femoral Head Necrosis. It uses aggregated published data instead of individual patient data and does not require an ethical board review and approval. The findings will be published in a peer-reviewed journal and disseminated in conference presentations.
The results of this study will offer implications of the use of TSD treatment for FHN with this meta-analysis.
The conclusion of this study will provide recent evidence to assess whether TSD is effective and safe in the treatment of FHN.
股骨头坏死是最常见的骨科疾病之一，可在各年龄段因不同原因而被诊断出来。桃红四物汤已广泛用于治疗股骨头坏死。然而，据我们所知，关于桃红四物汤治疗股骨头坏死的疗效仍缺乏支持证据。因此，本方案旨在评估桃红四物汤治疗股骨头坏死的有效性和安全性。
将检索8个电子数据库，包括PubMed、Cochrane对照试验中心注册库、EMBASE、科学引文索引、中国生物医学文献数据库、中国知网、维普数据库和万方数据库，检索时间从各数据库建立至2020年1月。收集桃红四物汤治疗股骨头坏死的随机对照试验。在评估方法学质量并提取有效数据后，将使用Revman 5.3软件进行最终的荟萃分析。
本系统评价的结果将为桃红四物汤治疗股骨头坏死的应用提供启示。它使用汇总的已发表数据而非个体患者数据，不需要伦理委员会审查和批准。研究结果将发表在同行评审期刊上，并在会议报告中传播。
本研究结果将通过该荟萃分析为桃红四物汤治疗股骨头坏死的应用提供启示。
本研究结论将为评估桃红四物汤治疗股骨头坏死是否有效和安全提供最新证据。
